SCHEMBL2061135

SCHEMBL2061135

Cc1c(N(Cc2ccc(OC(F)(F)F)cc2)S(=O)(=O)CCN2CCCC(C(F)(F)F)C2)sc2ccccc12

nearest known ligand 0.73

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 17/20 0.73
HTR7 P34969 1/20 0.39
CCR5 P51681 1/20 0.37
KDM2B Q8NHM5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2060818 0.91 TRPM8 (0.83) TRPM8CCR5
SCHEMBL2061192 0.90 TRPM8 (0.81) TRPM8
SCHEMBL2061023 0.90 TRPM8 (0.81) TRPM8
SCHEMBL2061065 0.89 TRPM8 (0.79) TRPM8
SCHEMBL2060707 0.88 TRPM8 (0.78) TRPM8CCR5
SCHEMBL2061113 0.87 TRPM8 (0.84) TRPM8CCR5
SCHEMBL2061048 0.86 TRPM8 (0.71) TRPM8
SCHEMBL2060648 0.86 TRPM8 (0.71) TRPM8
SCHEMBL10241194 0.86 TRPM8 (0.71) TRPM8
SCHEMBL2060688 0.86 TRPM8 (0.83) TRPM8CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379496-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2013-12-04 EP disclosed
US-8148422-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-03 US disclosed
US-8148422-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-03 US disclosed
US-8148422-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-03 US disclosed
EP-2379496-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2011-10-26 EP disclosed
WO-2010080398-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-15 WO disclosed
WO-2010080398-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-15 WO disclosed
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-06-24 US disclosed
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-06-24 US disclosed
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM2, TRPM5 TRPM8 1/4885HTR7 609/4885CCR5 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.